Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Apr;59(4):627–630. doi: 10.1038/bjc.1989.127

Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue.

A Thyss 1, G Milano 1, M C Etienne 1, P Paquis 1, J L Roche 1, P Grelier 1, M Schneider 1
PMCID: PMC2247158  PMID: 2785400

Abstract

In the first part of this study the availability of folinic acid (FA) and its main active circulating metabolite, 5-methyltetrahydrofolate (5-MTHF), were studied in plasma and cerebrospinal fluid (CSF) from normal subjects after i.v. administration of 100 and 250 mg of FA. 5-MTHF rapidly appeared in plasma, the maximum value being reached at the first observation time point (1 h). FA was eliminated in plasma more slowly than 5-MTHF. Between the two doses, there was no evidence of modification in pharmacokinetic parameters (terminal half-life, clearance) for either FA or 5-MTHF in plasma and CSF; 5-MTHF was the only product detectable in CSF. Considering FA plus 5-MTHF together, the AUC (area under the curve) ratios between CSF and plasma were close to 1%. 5-MTHF was cleared very slowly from CSF (t 1/2 = 85 h). This finding suggested possible accumulation of 5-MTHF in CSF during repeated administration of FA combined with medium or high dose MTX. In the second part of the study, dealing with a group of eight children treated by such protocols, an increase in CSF 5-MTHF was detected from cycle to cycle in five (r = 0.91, P less than 0.01) with a maximum at 5 x 10(-8) M. This progressive accumulation of 5-MTHF in CSF may have a negative effect on the local action of MTX and should be taken into account for therapeutic strategies designed for the management of meningeal leukaemia.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen J. C., Rosen G., Mehta B. M., Horten B. Leukoencephalopathy following high-dose iv methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep. 1980;64(12):1261–1273. [PubMed] [Google Scholar]
  2. Balis F. M., Savitch J. L., Bleyer W. A., Reaman G. H., Poplack D. G. Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol. 1985 Apr;3(4):485–489. doi: 10.1200/JCO.1985.3.4.485. [DOI] [PubMed] [Google Scholar]
  3. Bode U., Magrath I. T., Bleyer W. A., Poplack D. G., Glaubiger D. L. Active transport of methotrexate from cerebrospinal fluid in humans. Cancer Res. 1980 Jul;40(7):2184–2187. [PubMed] [Google Scholar]
  4. Borsi J. D., Moe P. J. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia. Cancer. 1987 Jul 1;60(1):5–13. doi: 10.1002/1097-0142(19870701)60:1<5::aid-cncr2820600103>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  5. Browman G. P., Spiegl P., Booker L., Rosowsky A. Comparison of leucovorin protection from variety of antifolates in human lymphoid cell lines. Cancer Chemother Pharmacol. 1985;15(2):111–114. doi: 10.1007/BF00257519. [DOI] [PubMed] [Google Scholar]
  6. Diddens H., Teufel T., Niethammer D. High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines. Cancer Chemother Pharmacol. 1987;20(2):128–132. doi: 10.1007/BF00253966. [DOI] [PubMed] [Google Scholar]
  7. Duttera M. J., Bleyer W. A., Pomeroy T. C., Leventhal C. M., Leventhal B. G. Irradiation, methotrexate toxicity, and the treatment of meningeal leukaemia. Lancet. 1973 Sep 29;2(7831):703–707. doi: 10.1016/s0140-6736(73)92539-7. [DOI] [PubMed] [Google Scholar]
  8. Freeman A. I., Weinberg V., Brecher M. L., Jones B., Glicksman A. S., Sinks L. F., Weil M., Pleuss H., Hananian J., Burgert E. O., Jr Comparison of intermediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children. N Engl J Med. 1983 Mar 3;308(9):477–484. doi: 10.1056/NEJM198303033080902. [DOI] [PubMed] [Google Scholar]
  9. Hamel E., Johnson G., Glaubiger D. Pharmacokinetics of leucovorin rescue using a new methotrexate-independent biochemical assay for leucovorin and N5-methyltetrahydrofolate. Cancer Treat Rep. 1981 Jul-Aug;65(7-8):545–553. [PubMed] [Google Scholar]
  10. Hryniuk W. M., Bertino J. R. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest. 1969 Nov;48(11):2140–2155. doi: 10.1172/JCI106181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jolivet J., Cowan K. H., Curt G. A., Clendeninn N. J., Chabner B. A. The pharmacology and clinical use of methotrexate. N Engl J Med. 1983 Nov 3;309(18):1094–1104. doi: 10.1056/NEJM198311033091805. [DOI] [PubMed] [Google Scholar]
  12. MacKintosh F. R., Colby T. V., Podolsky W. J., Burke J. S., Hoppe R. T., Rosenfelt F. P., Rosenberg S. A., Kaplan H. S. Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer. 1982 Feb 1;49(3):586–595. doi: 10.1002/1097-0142(19820201)49:3<586::aid-cncr2820490331>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  13. Packer R. J., Grossman R. I., Belasco J. B. High dose systemic methotrexate-associated acute neurologic dysfunction. Med Pediatr Oncol. 1983;11(3):159–161. doi: 10.1002/mpo.2950110304. [DOI] [PubMed] [Google Scholar]
  14. Payet B., Fabre G., Tubiana N., Cano J. P. Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatography. Cancer Chemother Pharmacol. 1987;19(4):319–325. doi: 10.1007/BF00261481. [DOI] [PubMed] [Google Scholar]
  15. Pollock R. J., Kaufman S. Dihydrofolate reductase is present in brain. J Neurochem. 1978 Jan;30(1):253–256. doi: 10.1111/j.1471-4159.1978.tb07059.x. [DOI] [PubMed] [Google Scholar]
  16. Reggev A., Djerassi I. Rescue from high-dose methotrexate with 5-methyltetrahydrofolate. Cancer Treat Rep. 1986 Feb;70(2):251–253. [PubMed] [Google Scholar]
  17. Straw J. A., Szapary D., Wynn W. T. Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res. 1984 Jul;44(7):3114–3119. [PubMed] [Google Scholar]
  18. Thyss A., Milano G., Deville A., Manassero J., Renee N., Schneider M. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies. Eur J Cancer Clin Oncol. 1987 Jun;23(6):843–847. doi: 10.1016/0277-5379(87)90289-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES